Sixteen in August. Back on schedule (thanks to jetlag).
1) Reducing Fatal Opioid Overdose: Prevention, Treatment and Harm Reduction Strategies.
Hawk KF, Vaca FE, D’Onofrio G.
Yale J Biol Med. 2015 Sep 3;88(3):235-245. eCollection 2015 Sep. Review.
Comment: Can’t access full article. Appears to be a review of harm reduction strategies for opioid overdose prevention.
2) Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update.
Brady KT, McCauley JL, Back SE.
Am J Psychiatry. 2015 Sep 4:appiajp201515020262. [Epub ahead of print]
Comment: Appropriately draws attention to the problem now faced in the United States: we are cutting back on opioid prescribing to try to limit further opioid dependence, but effectively abandoning many of the people who are already dependent.
DeVido J, Connery H, Hill KP.
J Opioid Manag. 2015 Jul-Aug;11(4):363-6. doi: 10.5055/jom.2015.0285.
Comment: Two case reports of sleep-disordered breathing among buprenorphine patients suggesting that buprenorphine may contribute to sleep apnea.
4) Buprenorphine infrequently found in fatal overdose in New York City.
Paone D, Tuazon E, Stajic M, Sampson B, Allen B, Mantha S, Kunins H.
Drug Alcohol Depend. 2015 Aug 15. pii: S0376-8716(15)01598-7. doi: 10.1016/j.drugalcdep.2015.08.007. [Epub ahead of print]
Comment: Actually, none of the decedents tested positive for buprenorphine – very few (2) were found to have positive toxicology for norbuprenorphine, a metabolite demonstrating recent – but not recent enough to be causal – consumption of buprenorphine. This is not surprising since it’s tough to overdose on buprenorphine. Nice work.
5) Risk Factors for Mortality and Endotracheal Intubation after Methadone Intoxication.
Hassanian-Moghaddam H, Soltaninejad K, Shadnia S, Kabir A, Movahed M, Mirafzal A.
Basic Clin Pharmacol Toxicol. 2015 Aug 24. doi: 10.1111/bcpt.12476. [Epub ahead of print]
Comment: Lower consciousness/respirations once in the emergency room were associated with increased likelihood of being intubated and/or dying from methadone overdose. This is interesting in the context of previous papers included on this blog that demonstrate lower likelihood of such outcomes when naloxone is administered in the field. Is it time to think of naloxone as an automated electronic defibrillator?
6) The characteristics of a cohort who tamper with prescribed and diverted opioid medications.
Larance B, Lintzeris N, Bruno R, Peacock A, Cama E, Ali R, Kihas I, Hordern A, White N, Degenhardt L.
J Subst Abuse Treat. 2015 Jun 24. pii: S0740-5472(15)00137-3. doi: 10.1016/j.jsat.2015.06.001. [Epub ahead of print]
Comment: This is a complex population. Although risk outcomes appear closer to those of someone who uses heroin than those of someone prescribed opioids, the clinical characteristics overlap substantially with the latter group.
Jackson JL.
J Gen Intern Med. 2015 Aug 19. [Epub ahead of print] No abstract available.
Comment: Summarizes the Bingswanger paper and that’s about it.
8) Factors associated with illicit methadone injecting in a Canadian setting.
Tucker D, Milloy MJ, Hayashi K, Nguyen P, Kerr T, Wood E.
Am J Addict. 2015 Sep;24(6):532-7. doi: 10.1111/ajad.12257. Epub 2015 Aug 18.
Comment: Really high-risk people inject methadone.
9) Gender differences in mortality among treated opioid dependent patients.
Evans E, Kelleghan A, Li L, Min J, Huang D, Urada D, Hser YI, Nosyk B.
Drug Alcohol Depend. 2015 Jul 17. pii: S0376-8716(15)00381-6. doi: 10.1016/j.drugalcdep.2015.07.010. [Epub ahead of print]
Comment: Some findings from a longitudinal study that I find hard to interpret and potentially specious.
Borriello R, Carfora A, Cassandro P, Petrella R.
Ann Clin Lab Sci. 2015 Jul;45(4):414-8.
Comment: The 6-MAM assay is pretty good.
Pirompanich P, Chankrachang S.
J Med Assoc Thai. 2015 Jul;98(7):703-8.
Comment: We’ve reviewed heroin-associated spongiform leukoencephalopathy before on this blog. This is another case identified in a heroin injector – instead of smoker – and review of the literature. Interestingly, this case was identified after an overdose.
Kiger ME, McCanta AC, Tong S, Schaffer M, Runciman M, Collins KK.
Pacing Clin Electrophysiol. 2015 Aug 8. doi: 10.1111/pace.12732. [Epub ahead of print]
Comment: There are some questions about the role of cardiac disease on overdose risk – this is pretty clearly the case for cocaine but not well understood for opioids. This report on WPW patients (WPW is an electrical conduction disease of the heart that affects repolarization of cardiac tissue and can result in potentially fatal arrhythmias in otherwise healthy people) refers briefly to a WPW patient who had to be resuscitated after methadone overdose. No further details unfortunately.
13) Orienting patients to greater opioid safety: models of community pharmacy-basednaloxone.
Green TC, Dauria EF, Bratberg J, Davis CS, Walley AY.
Harm Reduct J. 2015 Aug 6;12:25. doi: 10.1186/s12954-015-0058-x.
Comment: Two models of pharmacy provision of naloxone. Exciting work in New England.
LaBelle CT, Han SC, Bergeron A, Samet JH.
J Subst Abuse Treat. 2015 Jun 26. pii: S0740-5472(15)00146-4. doi: 10.1016/j.jsat.2015.06.010. [Epub ahead of print]
Comment: Describes an effort to expand buprenorphine treatment availability in Massachusetts.
15) Acute adult and adolescent poisoning in Tehran, Iran; the epidemiologic trend between 2006 and 2011.
Hassanian-Moghaddam H, Zamani N, Rahimi M, Shadnia S, Pajoumand A, Sarjami S.
Arch Iran Med. 2014 Aug;17(8):534-8. doi: 014178/AIM.003.
Comment: Interesting that pesticides match opioids as the two leading causes of poisoning death.
16) DOH issues emergency regulations on expanding use of Narcan to prevent opioidoverdose deaths.
[No authors listed]R I Med J (2013). 2014 Apr;97(4):49. No abstract available.
Comment: We should exercise caution in our use of the term “Narcan” in the future as the brand was purchased by the manufacturers of a nasal device that is likely to be approved in the near future. Promoting one brand over another is poor form in public health and academic venues.